Read more about the Part the Cloud Challenge on Inflammation Grant Recipients

Having trouble reading this email?
View it on your browser

Alzheimer's Association. The Brains Behind Saving Yours.

Dear Friends,

On the heels of our record-breaking Part the Cloud Gala in April, we wanted to once again thank you all for your generosity and support. This year, Part the Cloud raised over $10.8 million, bringing our total raised to over $17 million to support Alzheimer's disease clinical research.

We are also thrilled to share with you an update on the very exciting Part the Cloud Neuroinflammation Challenge. As announced in March, this first of its kind challenge on inflammation will accelerate therapeutics and discovery of innovative compounds to be used in early clinical trials. We received over 60 letters of interest from researchers in 14 countries and now, due to your overwhelming generosity, have selected not three, but four finalists who will receive $1,000,000 over a two year period and compete for an additional $3,000,000 in funding.

You can learn more about the challenge finalists and their projects below, as well as some additional updates from prior Part the Cloud grant recipients. In addition, we are in the throes of the next round Part the Cloud grants, which will be announced at our luncheon in early 2017. Stay tuned!

Thank you all again for your outstanding generosity to help us fund this important research, which will help us achieve our goal to slow and ultimately halt the expanding Alzheimer's disease crisis and give hope to millions who face and who will face the disease. Together, we will Part the Cloud!

Mikey Hoag and The Part the Cloud Committee

Featured Resources
Part the Cloud Website

Learn more about the PTC Grant Recipients

Learn more about the PTC Challenge on Neuroinflammation
Part the Cloud News and Updates
Part the Cloud Challenge on Inflammation Grant Recipients

Isidro Ferrer, M.D., Ph.D.
Bellvitge Biomedical Research Institute
Barcelona, Spain

Proposes a Phase II clinical trial to examine if Sativex reduces brain inflammation and helps slow the progression of Alzheimer's disease in people with mild cognitive impairment who may be at an increased risk for developing Alzheimer's.

John M. Olichney, M.D.
University of California, Davis

Proposes a Phase II clinical trial which will examine if the drug Senicapoc reduces brain inflammation and slows or prevents progression of Alzheimer's disease.

Anthony Andrew Oliva, Ph.D.
Longeveron, LLC
Miami, FL

Proposes a Phase I clinical study of whether (Adult) Mesenchymal Stem Cell Therapy for Neuroinflammation is safe and able to reduce brain inflammation in people with early Alzheimer's disease.

Huntington Potter, Ph.D.
University of Colorado, Denver

Proposes Phase II clinical trial to determine if the FDA-approved cancer drug, Leukine, is able to be repurposed as a safe and effective treatment to slow or prevent the progression of Alzheimer's.
2015 PTC Awardee Tim West in Final Stages of Testing Tau Antibody

Dr. Tim West, a 2015 PTC awardee, and the team at C2N are in the final stages of testing an additional dosage of their tau antibody. We expect this study to report out in the coming months on whether the experimental drug will move forward. Dr. West and his team have partnered with Abbvie so if their Phase 1 is successful, they will move into phase 2 quickly. Learn more.
Additional PTC Grant Recipient Updates
  • A trial led by Dr. Whitney Wharton, a 2015 PTC awardee at Emory University, looking at a drug used for cardiovascular disease in people with Alzheimer's disease has started to recruit individuals for their trial. Further, in collaboration with Dr. Malu Tansey, Dr. Wharton received a large NIH award of over $3 million to add additional outcomes of inflammation from blood and cerebrospinal fluid to their Part the Cloud trial.
  • Dr. Ahmed Salehi, a 2013 PTC awardee, and his team in another avenue of investigation have partnered with AC Immune, to establish a trial of their antibody ACI-24 vaccine targeting beta-amyloid in people with Down Syndrome to treat Alzheimer's disease. Learn more.
  • Dr. Stephen Cunnane, a 2014 PTC awardee, participated in a debate in the journal Scientific American on how access to shellfish as a food source helped the evolution of the human brains. Learn more.

For questions, please contact
View your email preferences or unsubscribe.